20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Kyverna Therapeutics, Inc. Common Stock (KYTX) operates in the BIOTECHNOLOGY industry and is headquartered in Emeryville, United States with about 149 employees. Its market capitalization is roughly $351 million. In the fiscal year ended 2025-12-31, KYTX reported $0M in revenue and ($161M) in net income.
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $7M | $6M |
| Gross Profit | — | ($2M) | ($2M) | ($2M) | $7M | $6M |
| Gross Margin % | — | — | — | — | 100.0% | 100.0% |
| Operating Income (EBIT) | ($159M) | ($170M) | ($143M) | ($62M) | ($29M) | ($26M) |
| Operating Margin % | — | — | — | — | -418.3% | -465.8% |
| Net Income | ($153M) | ($161M) | ($127M) | ($60M) | ($29M) | ($26M) |
| Net Margin % | — | — | — | — | -411.3% | -465.9% |
| EBITDA | ($149M) | ($159M) | ($125M) | ($58M) | ($28M) | ($26M) |
| Earnings Per Share (EPS) | $-2.94 | $-3.64 | $-3.33 | $-0.09 | $-1.12 | $-1.02 |
| Shares Outstanding (M) | 61M | 44M | 38M | — | 26M | 26M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $2M | $0M |
| Gross Profit | — | $0M | $0M | $0M | ($1M) | ($1M) | ($1M) | ($29M) |
| Gross Margin % | — | — | — | — | — | — | -27.8% | — |
| Operating Income (EBIT) | ($40M) | ($41M) | ($39M) | ($39M) | ($44M) | ($47M) | ($41M) | ($39M) |
| Operating Margin % | — | — | — | — | — | — | -2027.7% | — |
| Net Income | ($38M) | ($40M) | ($38M) | ($37M) | ($42M) | ($45M) | ($37M) | ($34M) |
| Net Margin % | — | — | — | — | — | — | -1852.2% | — |
| EBITDA | ($37M) | ($39M) | ($37M) | ($36M) | ($42M) | ($44M) | ($37M) | ($37M) |
| Earnings Per Share (EPS) | $-0.63 | $-0.66 | $-0.80 | $-0.85 | $-0.97 | $-1.03 | $-0.87 | $-0.80 |
| Shares Outstanding (M) | 61M | 60M | 47M | 43M | 43M | 43M | 43M | 43M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($159M) | ($154M) | ($114M) | ($52M) | ($36M) | ($22M) |
| Capital Expenditures (CapEx) | $1M | $0M | $2M | $1M | $1M | $1M |
| Free Cash Flow (FCF) | ($159M) | ($154M) | ($116M) | ($53M) | ($37M) | ($23M) |
| FCF Margin % | — | — | — | — | -525.0% | -414.5% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($40M) | ($42M) | ($34M) | ($43M) | ($32M) | ($45M) | ($37M) | ($27M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $1M | $0M |
| Free Cash Flow (FCF) | ($41M) | ($42M) | ($34M) | ($44M) | ($32M) | ($45M) | ($38M) | ($28M) |
| FCF Margin % | — | — | — | — | — | — | -1857.4% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Total Assets | $220M | $294M | $305M | $75M | $67M | $85M |
| Cash & Cash Equivalents | $32M | $124M | $97M | $35M | $38M | $76M |
| Total Liabilities | $54M | $62M | $38M | $26M | $141M | $132M |
| Total Debt (Short + Long-Term) | $26M | $29M | $4M | $3M | $2M | $1M |
| Total Shareholders' Equity | $166M | $232M | $267M | $49M | ($74M) | ($46M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive KYTX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms